A620脑电生物反馈治疗仪联合抗抑郁剂治疗抑郁症的临床效果评价

Evaluation of the Clinical Effect of A620 EEG Biofeedback Therapy Instrument Combined with Antidepressants in the Treatment of Depression

目的:探讨A620脑电生物反馈治疗仪联合抗抑郁剂治疗抑郁症的临床效果。方法:选择2017年9月~2019年1月本院收治的140例抑郁症患者,随机分为两组各70例,对照组单用抗抑郁剂治疗,观察组在对照组基础上采取A620脑电生物反馈治疗仪治疗。治疗前后采用汉密尔顿抑郁量表(HAMD)对患者进行评估,并检测血清5-羟色胺(5-HT)、多巴胺(DA)、去甲肾上腺素(NE)水平。结果:观察组治疗后HAMD评分为(13.42±2.19)分,明显低于对照组(17.03±2.59)分(P<0.05)。观察组治疗后的5-HT为(143.83±33.42)ng/mL,DA为(68.73±7.88)ng/L,NE为(79.18±13.25)ng/L,明显高于对照组(112.94±28.74)ng/mL,(45.06±6.16)ng/L,(52.08±12.77)ng/L,P<0.05。结论:A620脑电生物反馈治疗仪联合抗抑郁剂治疗抑郁症可获得更好的效果,可能与调节5-HT、DA和NE的表达有关。

Objective:To explore the clinical effect of A620 EEG biofeedback therapy instrument combined with antidepressants in the treatment of depression.Methods:Select 140 depression patients admitted to our hospital from September 2017 to January 2019,and randomly divide them into two groups with 70 cases each.The control group was treated with antidepressant alone,and the study group was treated with A620 brain on the basis of the control group.Electric biofeedback therapy instrument treatment.Before and after treatment,the patients were evaluated with the Hamilton Depression Scale(HAMD),and the serum levels of 5-hydroxytryptamine(5-HT),dopamine(DA)and norepinephrine(NE)were measured.Results:The HAMD score of the study group after treatment was(13.42±2.19)points,which was significantly lower than the control group(17.03±2.59)points(P<0.05).After treatment,5-HT of the study group was(143.83±33.42)ng/mL,DA was(68.73±7.88)ng/L,and NE was(79.18±13.25)ng/L,which was significantly higher than that of the control group(112.94±28.74)ng/mL,(45.06±6.16)ng/L,(52.08±12.77)ng/L(P<0.05).Conclusion:A620 EEG biofeedback therapy instrument combined with antidepressants can achieve better results in the treatment of depression,which may be related to the regulation of the expression of 5-HT,DA and NE.